Paper Details

  1. Home
  2. Paper Details

Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors.

Author: AgricolaKaren, CapalJamie K, FranzDavid N, KruegerDarcy A, RitterDavid M, StiresGabrielle

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Everolimus and sirolimus, mammalian target of rapamycin inhibitors, are effective treatments for various clinical manifestations of tuberous sclerosis complex, including subependymal giant cell astrocytoma and epilepsy. While generally well tolerated with manageable side effects, these medications may also lead to rare adverse effects, requiring close monitoring.
Paper Details　
Original Abstract of the Article :
Tuberous sclerosis complex (TSC) is a genetic disorder that is manifested in multiple body systems. A mammalian target of rapamycin (mTOR) inhibitor (mTORi), either everolimus or sirolimus, is now routinely prescribed for multiple clinical manifestations of TSC, including subependymal giant cell ast...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.pediatrneurol.2021.03.007

データ提供：米国国立医学図書館（NLM）

mTOR Inhibitors: Navigating the Landscape of Tuberous Sclerosis Complex

This research delves into the world of [genetics], specifically addressing the challenges of managing [tuberous sclerosis complex (TSC)]. This condition, like a desert sandstorm that disrupts the natural balance of an ecosystem, can lead to a variety of health complications. The researchers explore the use of [mTOR inhibitors (mTORi)] to treat TSC, focusing on the medications [everolimus] and [sirolimus]. This approach, akin to studying the effects of a specific desert plant on different aspects of the environment, allows researchers to understand the potential benefits and risks of these medications. Their findings highlight the effectiveness of mTOR inhibitors in managing TSC, providing a beacon of hope for those living with this complex condition.

Harnessing the Power of mTOR Inhibitors

This research underscores the effectiveness of mTOR inhibitors in managing tuberous sclerosis complex (TSC). This finding, like a well-constructed desert irrigation system, offers a way to manage the challenges posed by this condition and potentially improve the lives of those affected.

Living Well with Tuberous Sclerosis Complex

This research offers a glimmer of hope for individuals living with TSC. The study suggests that mTOR inhibitors, particularly everolimus and sirolimus, can effectively manage the condition and potentially improve quality of life. It is crucial to work closely with a qualified healthcare professional to navigate the complexities of TSC treatment and make informed decisions about the best course of action.

Dr.Camel's Conclusion

This research sheds light on the effectiveness of mTOR inhibitors in managing tuberous sclerosis complex (TSC). The authors meticulously investigated the use of everolimus and sirolimus, highlighting the medications' potential to manage TSC and improve quality of life. Like a skilled desert traveler discovering a new oasis, this research offers valuable insights into the management of this complex condition and provides a path toward a brighter future for those living with TSC.
Date :
  1. Date Completed 2022-02-02
  2. Date Revised 2022-02-02
Further Info :

Pubmed ID

33962348

DOI: Digital Object Identifier

10.1016/j.pediatrneurol.2021.03.007

Related Literature

Article Analysis
・Side Effects of everolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.